Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Patient characteristics according to survival status at 18 monthsBaseline characteristicSurvivors(n = 116)Non-survivors(n = 27) P Age, mean years (SD)76.32 (7.37)82.4 (8.4)< 0.001Female sex, n (%)53 (45.7)11 (40.7)0.674Influenza vaccine, n (%)66 (56.9)25 (92.6)< 0.00113v Pneumococcal vaccine, n (%)6 (5.2%)2 (7.4)0.64623v Pneumococcal vaccine, n (%)59 (50.9)23 (85.2)< 0.001Charlson comorbidity index, mean (SD)1.35 (1.56)3.16 (2.15)< 0.001Main comorbidities: Acute myocardial infarction, n (%)6 (5.2)7 (25.9)0.003 Congestive heart failure, n (%)16 (13.8)7 (25.9)0.146 Peripheral vascular disease, n (%)4 (3.4)6 (22.2)0.003 Cerebrovascular disease, n (%)12 (10.3)2 (7.4)1 Dementia, n (%)3 (2.6)5 (18.5)0.006 COPD, n (%)32 (27.6)9 (33.3)0.637 Rheumatic disease, n (%)3 (2.6)1 (3.7)0.571 Peptic ulcer, n (%)1 (0.9)2 (7.4)0.091 Mild to moderate diabetes, n (%)26 (22.4)7 (25.9)0.8 Mild hepatopathy, n (%)2 (1.7)01 Chronic kidney diseasea, n (%)7 (6)10 (37)< 0.001 Diabetes with chronic complications, n (%)4 (3.4)6 (22.2)0.003 Tumour9 (7.8)00.208 Leukaemia, n (%)1 (0.9)1 (3.7)0.343 PSI, mean (SD)93.2 (21.7)118.1 (32.8)< 0.001 SARSCoV2 positivity, n (%)41 (35.3)0< 0.001 Frailtyb, n (%)32 (27.6)19 (70.4)< 0.001 BMI, mean (SD)27.73 (4.81)23.97 (5.70)< 0.001 Barthel Index, mean (SD)88.77 (16.10)60.0 (29.54)< 0.001 MNA, mean (SD)21.98 (3.91)14.52 (4.78)< 0.001 Cholesterol mmol/L, mean (SD)5.22 (1.07)3.98 (1.27)< 0.001 Triglycerides mmol/L, mean (SD)1.50 (0.79)1.29 (0.59)0.188 CRP mg/L, mean (SD)6.73 (11.5)29.7 (42.1)< 0.001 Calcium mmol/L, mean (SD)2.32 (0.14)2.21 (0.13)< 0.001 Albumin g/L, mean (SD)39.94 (3.24)34.7 (3.84)< 0.001 Pre-albumin g/L, mean (SD)0.26 (0.06)0.20 (0.06)< 0.001 Vitamin D nmol/l, mean (SD)52.94 (32.0)41.75 (26.7)0.127 Hb, mean (SD)126.83 (17.63)115.68 (19.07)0.001 Leucocytes, mean (SD)6906.2 (2243.2)8243.4 (3639.6)0.004 Lymphocytes, mean (SD)1688.0 (722.9)1296.3 (596.9)0.008 Lymphopenia, n (%)48 (41.3)18 (66.6)0.018 IRP, n (%)52 (44.8)15 (55.5)0.314IRP criteria: Positive CMV serology, n (%)100 (86.2)24 (88.8)0.712 Lymphocytes T CD28: c, n (%)54 (46.1)14 (51.8)0.647 Lymphocytes T CD8 + d, n (%)23 (19.8)4 (14.8)0.549 Lymphocytes T CD4/CD8 < 1, n (%)17 (14.6)5 (18.5)0.616Abbreviations: SD Standard deviation, COPD Chronic obstructive pulmonary disease, PSI Pneumonia Severity Index, BMI Body mass index, MNA Mini Nutritional Assessment, CRP C-reactive protein, Hb Haemoglobin, IRP immune risk phenotype, CMV CytomegalovirusaChronic kidney disease assessed according to CCI (level of serum creatinine > 265 pmol/L, being on dialysis, being a recipient of renal transplantation, or presenting uraemia)b Frailty definition according to Fried’s criteriacTCD8 CD28: lymphocytes count > 300 / µld CD8 T-cells lymphocyte count > 600/ µl

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a prospective cohort study conducted at the Hospital de la Santa Creu i Sant Pau, a tertiary university hospital in Barcelona, Spain.

Source: Methods.

Patients aged 65 or older with radiologically-confirmed pneumonia requiring hospitalisation between May 2019 and July 2021 were invited to participate.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Immune risk phenotype and long-term mortality after community-acquired pneumonia in older adults: clinical and immune determinants

Cohort study · Immunity & Ageing : I & A · 2026

Original publication title

Immune risk phenotype and long-term mortality after community-acquired pneumonia in older adults: clinical and immune determinants

Sandra Clotet-Vidal; Teresa Franco-Leyva; Encarna Saez Prieto; Laura Feltrer Martinez; Alvaro Izquierdo Cardenas; Laura Martínez-Martínez; Jordi Casademont Pou; Olga H. Torres Bonafonte

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study underscores the role of infectious complications in long-term outcomes after CAP. These findings highlight the need for comprehensive geriatric assessment to identify multidimensional risk factors, including immunosenescence as a potentially modifiable domain warranting further investigation and integration into care.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To assess 18-month mortality after CAP hospitalisation and the prognostic value of the Immune Risk Phenotype (IRP).

Source: Objective

Abstract: What methods does the paper describe?

Prospective, observational study of adults ≥ age 65 years discharged after CAP (2019 to 21). We performed comprehensive geriatric and nutritional assessments, including laboratory tests at 30 to 60 days post diagnosis. IRP was defined as cytomegalovirus seropositivity with inverted CD4:CD8 ratio, elevated CD8 + T cell count, or expansion of CD8CD28-T cells. The main outcome measure was 18-month mortality. Multivariate logistic with ROC curves and Cox regression analyses were performed. (ClinicalTrials.gov, NCT0462799).

Source: Methods

Abstract: Results

The sample included 143 patients (55.2% males), with a mean age of 77.6 ± 7.9 years. IRP was found in 46.8% of patients. Elevated lymphocyte count and female sex were predictors of IRP. At 18 months post-CAP, 27 patients (18%) had died, mainly due to infections (n = 13, 48%) and fractures (n = 2, 7.4%). Predictors of 18-month mortality included IRP (HR 2.58 [95% CI 1.11 to 5.99]; p = 0.027), severe chronic kidney disease (6.16 [2.53 to 14.99]; p<0.001), poor functional status (3.69 [1.53 to 8.90] p = 0.004), and hypoalbuminemia (3.35; [1.34 to 8.41]; p = 0.010).

Source: Results

Abstract: Conclusions

This study underscores the role of infectious complications in long-term outcomes after CAP. These findings highlight the need for comprehensive geriatric assessment to identify multidimensional risk factors, including immunosenescence as a potentially modifiable domain warranting further investigation and integration into care.

Source: Conclusions
Authors’ abstract

Background

Community-acquired pneumonia (CAP) has been associated with poor long-term outcomes in older adults. In most pre-pandemic studies, long-term mortality was assessed with a focus on comorbidity burden. Although immunosenescence is a key determinant of CAP, post-acute immune patterns have been little explored.

Objective

To assess 18-month mortality after CAP hospitalisation and the prognostic value of the Immune Risk Phenotype (IRP).

Methods

Prospective, observational study of adults ≥ age 65 years discharged after CAP (2019 to 21). We performed comprehensive geriatric and nutritional assessments, including laboratory tests at 30 to 60 days post diagnosis. IRP was defined as cytomegalovirus seropositivity with inverted CD4:CD8 ratio, elevated CD8 + T cell count, or expansion of CD8CD28-T cells. The main outcome measure was 18-month mortality. Multivariate logistic with ROC curves and Cox regression analyses were performed. (ClinicalTrials.gov, NCT0462799).

Results

The sample included 143 patients (55.2% males), with a mean age of 77.6 ± 7.9 years. IRP was found in 46.8% of patients. Elevated lymphocyte count and female sex were predictors of IRP. At 18 months post-CAP, 27 patients (18%) had died, mainly due to infections (n = 13, 48%) and fractures (n = 2, 7.4%). Predictors of 18-month mortality included IRP (HR 2.58 [95% CI 1.11 to 5.99]; p = 0.027), severe chronic kidney disease (6.16 [2.53 to 14.99]; p<0.001), poor functional status (3.69 [1.53 to 8.90] p = 0.004), and hypoalbuminemia (3.35; [1.34 to 8.41]; p = 0.010).

Conclusions

This study underscores the role of infectious complications in long-term outcomes after CAP. These findings highlight the need for comprehensive geriatric assessment to identify multidimensional risk factors, including immunosenescence as a potentially modifiable domain warranting further investigation and integration into care.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12979-026-00574-8.

Publication and source details

Original title: Immune risk phenotype and long-term mortality after community-acquired pneumonia in older adults: clinical and immune determinants

Sandra Clotet-Vidal; Teresa Franco-Leyva; Encarna Saez Prieto; Laura Feltrer Martinez; Alvaro Izquierdo Cardenas; Laura Martínez-Martínez; Jordi Casademont Pou; Olga H. Torres Bonafonte

Immunity & Ageing : I & A · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100004587Instituto de Salud Carlos IIIPI18/00684PI18/00684PI18/00684PI18/00684Clotet-Vidal Sandra Saez Prieto Encarna Casademont Pou Jordi Torres Bonafonte Olga H. https://doi.org/10.13039/501100008530European Regional Development Fund

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:22:37.673668+00:00

DOI: 10.1186/s12979-026-00574-8 · PMC13463403